Iris A. Simons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iris A. Simons has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Esther J. Nossent
Amsterdam UMC location Vrije Universiteit Amsterdam, Pulmonary Medicine, Amsterdam, the Netherlands
3 shared publications - JanWillem Duitman
Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
3 shared publications A.H. Maitland-Van der Zee
Amsterdam UMC location University of Amsterdam, Pulmonary Medicine, Amsterdam, The Netherlands
1 shared publication- Anke-Hilse Maitland-Van der Zee
Department of Pulmonary Medicine, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands
1 shared publication - Arlette Odink
Radiology and Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, Rotterdam, Zuid-Holland, 3015 GD, NETHERLANDS
1 shared publication Bart G. Boerrigter
Amsterdam UMC location Vrije Universiteit Amsterdam, Pulmonary Medicine, De Boelelaan 1117, Amsterdam, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 17 September 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Circulating Surfactant Proteins B and D are associated with Interstitial Lung Abnormalities and their Progression
Extract Interstitial lung abnormalities (ILA) are incidental CT findings, characterised by non-dependent parenchymal abnormalities -as ground-glass opacities, reticulation, and traction bronchiectasis- affecting at least 5% of a lung zone [1]. Their detection is increasing with widespread CT use in e.g. cancer screening and cardiovascular diagnostic imaging. Prevalence ranges from 2 to 35%, occurring commonly in older individuals, smokers, and those with a family history of interstitial lung disease (ILD).
- 17 September 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessCirculating Surfactant Proteins B and D are associated with Interstitial Lung Abnormalities and their Progression
Extract Interstitial lung abnormalities (ILA) are incidental CT findings, characterised by non-dependent parenchymal abnormalities -as ground-glass opacities, reticulation, and traction bronchiectasis- affecting at least 5% of a lung zone [1]. Their detection is increasing with widespread CT use in e.g. cancer screening and cardiovascular diagnostic imaging. Prevalence ranges from 2 to 35%, occurring commonly in older individuals, smokers, and those with a family history of interstitial lung disease (ILD).
- Open Access
- 9 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 220, 111588
Outcomes of stereotactic ablative radiotherapy or surgery for early-stage lung cancer in patients with interstitial lung disease
- 9 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 220, 111588
Open AccessOutcomes of stereotactic ablative radiotherapy or surgery for early-stage lung cancer in patients with interstitial lung disease
- Open Access
- 9 January 2026
- Published by IOP Publishing in Journal of Breath Research
- Vol. 20 (1) , 016005
Gas chromatography-mass spectrometry exhaled breath analysis for phenotyping interstitial lung disease- an exploratory study
Interstitial lung disease (ILD) encompasses pulmonary disorders characterised by varying degrees of inflammation and/or fibrosis. The presence and extent of these pulmonary abnormalities on (high-resolution) computed tomography (CT) have consequences for diagnosis and treatment; however, inter-observer assessment varies. Analysis of exhaled volatile organic compounds (VOCs) through gas chromatography-mass spectrometry (GC-MS) offers a noninvasive approach to biomarker discovery and pathophysiology understanding. Our study aims to explore the ability of GC-MS-driven exhaled breath analysis to differentiate ILD patients with predominant fibrotic, inflammatory, or a combination of fibrotic and inflammatory pulmonary abnormalities in a training and an external validation cohort. In a multicentre cross-sectional study, patients diagnosed with ILD were recruited. After central review of chest CT scans by independent radiologists, patients were categorised as fibrotic, inflammatory or mixed phenotype group based on the percentage of chest CT scan abnormalities. Breath samples were collected and analysed via GC-MS. Significantly different VOC fragments between groups were selected and used to differentiate groups in the training cohort with sparse partial least squares discriminant analysis. Analyses were validated with patients from an external cohort. 53 patients were included, 21 patients in the fibrotic, 14 in the inflammatory and 18 in the mixed phenotype group. Area under the curve (AUCs) for discrimination between groups ranged from 0.89–1.00 in training cohorts. An attempt to confirm these findings in our external validation cohort resulted in AUCs of 0.63–0.84. Re-evaluation of the training model led to an AUC of 0.78–0.83. This study shows that GC-MS driven exhaled breath analysis towards differentiation of ILD phenotypes is challenging. Current findings emphasise the importance of predefined validation steps during the process of biomarker discovery.
- 9 January 2026
- Published by IOP Publishing in Journal of Breath Research
- Vol. 20 (1) , 016005
Open AccessGas chromatography-mass spectrometry exhaled breath analysis for phenotyping interstitial lung disease- an exploratory study
Interstitial lung disease (ILD) encompasses pulmonary disorders characterised by varying degrees of inflammation and/or fibrosis. The presence and extent of these pulmonary abnormalities on (high-resolution) computed tomography (CT) have consequences for diagnosis and treatment; however, inter-observer assessment varies. Analysis of exhaled volatile organic compounds (VOCs) through gas chromatography-mass spectrometry (GC-MS) offers a noninvasive approach to biomarker discovery and pathophysiology understanding. Our study aims to explore the ability of GC-MS-driven exhaled breath analysis to differentiate ILD patients with predominant fibrotic, inflammatory, or a combination of fibrotic and inflammatory pulmonary abnormalities in a training and an external validation cohort. In a multicentre cross-sectional study, patients diagnosed with ILD were recruited. After central review of chest CT scans by independent radiologists, patients were categorised as fibrotic, inflammatory or mixed phenotype group based on the percentage of chest CT scan abnormalities. Breath samples were collected and analysed via GC-MS. Significantly different VOC fragments between groups were selected and used to differentiate groups in the training cohort with sparse partial least squares discriminant analysis. Analyses were validated with patients from an external cohort. 53 patients were included, 21 patients in the fibrotic, 14 in the inflammatory and 18 in the mixed phenotype group. Area under the curve (AUCs) for discrimination between groups ranged from 0.89–1.00 in training cohorts. An attempt to confirm these findings in our external validation cohort resulted in AUCs of 0.63–0.84. Re-evaluation of the training model led to an AUC of 0.78–0.83. This study shows that GC-MS driven exhaled breath analysis towards differentiation of ILD phenotypes is challenging. Current findings emphasise the importance of predefined validation steps during the process of biomarker discovery.
- Open Access
- 1 April 2025
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 34 (176) , 240282
Prognostic biomarkers for the development of progressive pulmonary fibrosis in hypersensitivity pneumonitis: a systematic review
Background: In fibrotic hypersensitivity pneumonitis (fHP) an ongoing immune response triggers pulmonary inflammation and concurrent fibrotic pathways, leading to irreversible disease progression. Patients with the progressive pulmonary fibrosis (PPF) phenotype have a poor prognosis. Reliable identification of biomarkers to predict PPF could aid clinicians in determining disease prognosis and optimising patient care. We aimed to identify prognostic biomarkers for the PPF phenotype in fHP using existing literature.Methods: We performed a systematic review (PROSPERO, CRD42024537599) and searched Medline, Embase and Scopus from inception to 10 April 2024. We included studies that evaluated the ability of biomarkers measured in blood or bronchoalveolar lavage fluid (BALF) to predict disease progression in adult patients with fHP. Study quality was assessed using the Quality Assessment of Prognostic Accuracy Studies tool.Results: Of the 3027 articles initially identified, 31 met the inclusion criteria, encompassing a total of 3766 fHP patients. 65 biomarkers were identified; however, most were evaluated in only one (n=49) or two (n=6) studies. The most frequently evaluated biomarkers were BALF cellular composition, serum Krebs von den Lungen-6 and serum surfactant protein D levels. Survival was the most commonly assessed outcome, followed by disease progression and acute exacerbation. None of the biomarkers reliably predicted the prognosis.Conclusions: A large number of biomarkers have been evaluated for their prognostic ability in fHP, but none of them appear to be consistently associated with the PPF phenotype. Heterogeneity across studies in terms of methods, disease definitions, outcomes and measurement time points complicates the identification of a marker with strong potential, and this situation should be improved in the clinical field.
- 1 April 2025
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 34 (176) , 240282
Open AccessPrognostic biomarkers for the development of progressive pulmonary fibrosis in hypersensitivity pneumonitis: a systematic review
Background: In fibrotic hypersensitivity pneumonitis (fHP) an ongoing immune response triggers pulmonary inflammation and concurrent fibrotic pathways, leading to irreversible disease progression. Patients with the progressive pulmonary fibrosis (PPF) phenotype have a poor prognosis. Reliable identification of biomarkers to predict PPF could aid clinicians in determining disease prognosis and optimising patient care. We aimed to identify prognostic biomarkers for the PPF phenotype in fHP using existing literature.Methods: We performed a systematic review (PROSPERO, CRD42024537599) and searched Medline, Embase and Scopus from inception to 10 April 2024. We included studies that evaluated the ability of biomarkers measured in blood or bronchoalveolar lavage fluid (BALF) to predict disease progression in adult patients with fHP. Study quality was assessed using the Quality Assessment of Prognostic Accuracy Studies tool.Results: Of the 3027 articles initially identified, 31 met the inclusion criteria, encompassing a total of 3766 fHP patients. 65 biomarkers were identified; however, most were evaluated in only one (n=49) or two (n=6) studies. The most frequently evaluated biomarkers were BALF cellular composition, serum Krebs von den Lungen-6 and serum surfactant protein D levels. Survival was the most commonly assessed outcome, followed by disease progression and acute exacerbation. None of the biomarkers reliably predicted the prognosis.Conclusions: A large number of biomarkers have been evaluated for their prognostic ability in fHP, but none of them appear to be consistently associated with the PPF phenotype. Heterogeneity across studies in terms of methods, disease definitions, outcomes and measurement time points complicates the identification of a marker with strong potential, and this situation should be improved in the clinical field.